Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.42 |
| ▸ | TBK1 | Q9UHD2 | 1/20 | 0.41 |
| ▸ | EGFR | P00533 | 2/20 | 0.40 |
| ▸ | BTK | Q06187 | 2/20 | 0.40 |
| ▸ | MELK | Q14680 | 4/20 | 0.39 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.39 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 2/20 | 0.38 |
| ▸ | PRKAA2 | P54646 | 1/20 | 0.37 |
| ▸ | S1PR5 | Q9H228 | 1/20 | 0.37 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.36 |
| ▸ | GRM5 | P41594 | 1/20 | 0.36 |
| ▸ | LTA4H | P09960 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12443126 | 0.91 | EGFR (0.39) | EGFRBTKCHRM4POLBHRH3 | |
| SCHEMBL3651887 | 0.89 | PTK2 (0.47) | CHRM4PTK2POLBPRKAA2S1PR5 | |
| SCHEMBL3650207 | 0.85 | GPR6 (0.41) | EGFRBTKCHRM4PTK2POLB | |
| SCHEMBL3652561 | 0.85 | EGFR (0.40) | EGFRBTKCHRM4PTK2POLB | |
| SCHEMBL12788855 | 0.85 | HRH3 (0.44) | TBK1MELKHRH3GRM5LTA4H | |
| SCHEMBL3644492 | 0.85 | LTA4H (0.49) | EGFRPTK2S1PR5HRH3LTA4H | |
| SCHEMBL3650935 | 0.84 | ACHE (0.40) | EGFRBTKCHRM4PTK2POLB | |
| SCHEMBL3651441 | 0.84 | EGFR (0.46) | TBK1EGFRBTKMELKCHRM4 | |
| SCHEMBL3647442 | 0.84 | LTA4H (0.42) | EGFRBTKCHRM4PTK2POLB | |
| SCHEMBL27807596 | 0.83 | GRM5 (0.39) | EGFRBTKMELKPTK2POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8288540-B2 | 2-heteroarylamino-pyrimidine derivatives as kinase inhibitors | IRM LLC (BM) | 2012-10-16 | — | — | US | disclosed |
| EP-2190836-B1 | 2-HETEROARYLAMINO-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2011-08-17 | — | — | EP | disclosed |
| US-20110053952-A1 | 2-HETEROARYLAMINO-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2011-03-03 | — | — | US | disclosed |
| WO-2009026204-A1 | 2-HETEROARYLAMINO-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | IRM LLC (BM) | 2009-02-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110053952-A1 | 2-HETEROARYLAMINO-PYRIMIDINE DERIVATIVES AS KINASE INHIBITORS | FYN, LCK, ERBB2 | L3MBTL1 3713/4885TBK1 747/4885EGFR 115/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.